Emerging  ||| S:0 E:9 ||| VBG
technologies  ||| S:9 E:22 ||| NNS
Hemodynamic  ||| S:22 E:34 ||| JJ
monitoring  ||| S:34 E:45 ||| NN
in  ||| S:45 E:48 ||| IN
critically  ||| S:48 E:59 ||| RB
ill  ||| S:59 E:63 ||| JJ
patients  ||| S:63 E:72 ||| NNS
has  ||| S:72 E:76 ||| VBZ
been  ||| S:76 E:81 ||| VBN
considered  ||| S:81 E:92 ||| VBN
part  ||| S:92 E:97 ||| NN
of  ||| S:97 E:100 ||| IN
the  ||| S:100 E:104 ||| DT
standard  ||| S:104 E:113 ||| NN
of  ||| S:113 E:116 ||| IN
care  ||| S:116 E:121 ||| NN
in  ||| S:121 E:124 ||| IN
managing  ||| S:124 E:133 ||| VBG
patients  ||| S:133 E:142 ||| NNS
with  ||| S:142 E:147 ||| IN
shock  ||| S:147 E:153 ||| NN
and ||| S:153 E:156 ||| CC
/ ||| S:156 E:157 ||| NNP
or  ||| S:157 E:160 ||| CC
acute  ||| S:160 E:166 ||| JJ
lung  ||| S:166 E:171 ||| NN
injury ||| S:171 E:177 ||| NN
,  ||| S:177 E:179 ||| ,
but  ||| S:179 E:183 ||| CC
outcome  ||| S:183 E:191 ||| NN
benefit ||| S:191 E:198 ||| NN
,  ||| S:198 E:200 ||| ,
particularly  ||| S:200 E:213 ||| RB
in  ||| S:213 E:216 ||| IN
pediatric  ||| S:216 E:226 ||| JJ
patients ||| S:226 E:234 ||| NNS
,  ||| S:234 E:236 ||| ,
has  ||| S:236 E:240 ||| VBZ
been  ||| S:240 E:245 ||| VBN
questioned ||| S:245 E:255 ||| VBN
.  ||| S:255 E:257 ||| .
There  ||| S:257 E:263 ||| EX
is  ||| S:263 E:266 ||| VBZ
difficulty  ||| S:266 E:277 ||| NN
in  ||| S:277 E:280 ||| IN
validating  ||| S:280 E:291 ||| VBG
the  ||| S:291 E:295 ||| DT
reliability  ||| S:295 E:307 ||| NN
of  ||| S:307 E:310 ||| IN
monitoring  ||| S:310 E:321 ||| VBG
devices ||| S:321 E:328 ||| NNS
,  ||| S:328 E:330 ||| ,
especially  ||| S:330 E:341 ||| RB
since  ||| S:341 E:347 ||| IN
this  ||| S:347 E:352 ||| DT
validation  ||| S:352 E:363 ||| NN
requires  ||| S:363 E:372 ||| VBZ
comparison  ||| S:372 E:383 ||| NN
to  ||| S:383 E:386 ||| TO
the  ||| S:386 E:390 ||| DT
pulmonary  ||| S:390 E:400 ||| JJ
artery  ||| S:400 E:407 ||| NN
catheter ||| S:407 E:415 ||| NN
,  ||| S:415 E:417 ||| ,
which  ||| S:417 E:423 ||| WDT
has  ||| S:423 E:427 ||| VBZ
its  ||| S:427 E:431 ||| PRP$
own  ||| S:431 E:435 ||| JJ
problems  ||| S:435 E:444 ||| NNS
as  ||| S:444 E:447 ||| IN
a  ||| S:447 E:449 ||| DT
measurement  ||| S:449 E:461 ||| NN
tool ||| S:461 E:465 ||| NN
.  ||| S:465 E:467 ||| .
Interpretation  ||| S:467 E:482 ||| NN
of  ||| S:482 E:485 ||| IN
the  ||| S:485 E:489 ||| DT
available  ||| S:489 E:499 ||| JJ
evidence  ||| S:499 E:508 ||| NN
reveals  ||| S:508 E:516 ||| VBZ
advantages  ||| S:516 E:527 ||| NNS
and  ||| S:527 E:531 ||| CC
disadvantages  ||| S:531 E:545 ||| NNS
of  ||| S:545 E:548 ||| IN
the  ||| S:548 E:552 ||| DT
available  ||| S:552 E:562 ||| JJ
hemodynamic  ||| S:562 E:574 ||| JJ
monitoring  ||| S:574 E:585 ||| NN
devices ||| S:585 E:592 ||| NNS
.  ||| S:592 E:594 ||| .
